{"schema_version":"secwatch.filing_event.v1","accession":"0001396814-23-000035","form_type":"8-K","ticker":"PCRX","cik":"0001396814","company_name":"Pacira BioSciences, Inc.","filed_at":"2023-08-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.782767+00:00","generated_at":"2026-06-12T12:29:32.359261+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Pacira Q2 net income $25.8M; EXPAREL guidance cut to $550-560M","bullets":["Total revenue $169.5M flat YoY; EXPAREL net sales $135.1M down from $137.0M.","GAAP net income $25.8M ($0.51 diluted EPS) vs $19.9M ($0.40) YoY; adjusted EBITDA $54.3M.","Lowers FY2023 EXPAREL guidance to $550-560M from $570-580M; ZILRETTA to $110-115M.","Cash $220.8M; operating cash flow $43.5M vs $29.8M YoY.","Non-GAAP gross margin guidance cut to 73-74% from prior 76-78%."],"urls":{"canonical":"https://secwatch.observer/filing/0001396814-23-000035","json":"https://secwatch.observer/filing/0001396814-23-000035.json","markdown":"https://secwatch.observer/filing/0001396814-23-000035.md","text":"https://secwatch.observer/filing/0001396814-23-000035.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1396814/000139681423000035/0001396814-23-000035-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1396814/000139681423000035/pcrx-20230802.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T12:29:32.359261+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1abd4fe692716e5cbaa0ed862d4ed5ef17013f8f","claim":"Pacira BioSciences, Inc. reported the second quarter ended June 30, 2023 results: revenue Total revenues of $169.5 million, net income Net income of $25.8 million, EPS $0.56 per share (basic) and $0.51 per share (diluted). Guidance lowered.","evidence_excerpt":"Total revenues of $169.5 million • Net product sales of $135.1 million for EXPAREL, $29.3 million for ZILRETTA, and $4.4 million for iovera° • Net income of $25.8 million, or $0.56 per share (basic) and $0.51 per share (diluted)","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1396814/000139681423000035/0001396814-23-000035-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Revenue","value":"Total revenues of $169.5 million"},{"label":"Net income","value":"Net income of $25.8 million"},{"label":"EPS","value":"$0.56 per share (basic) and $0.51 per share (diluted)"},{"label":"Guidance","value":"lowered"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"b2b78b75bff23941dff8c18beea6b3c6769fc416","claim":"Pacira BioSciences, Inc. updated its full year 2023 guidance (lowered).","evidence_excerpt":"Pacira is revising the following full-year financial guidance: • EXPAREL net product sales of $550 million to $560 million versus the company’s previously guided range of $570 million to $580 million; • ZILRETTA net product sales of $110 million to $115 million versus the company’s previously guided range of $115 million to $125 million; • Non-GAAP gross margin of 73% to 74% versus the company’s previously guided range of 76% to 78%; and • Stock-based compensation of $46 million to $49 million versus the company’s previously guided range of $51 million to $54 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1396814/000139681423000035/0001396814-23-000035-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2023"},{"label":"Guidance","value":"lowered"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}